Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxart, Inc. (VXRT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain the contents of each document in clear language. As a clinical-stage biotechnology company developing oral recombinant pill vaccines, Vaxart uses its filings to report on clinical progress, collaborations, listing status and material agreements that shape its vaccine platform and financial position.
Through Vaxart’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, investors can review detailed discussions of its oral vaccine programs for coronavirus, norovirus, influenza and HPV, as well as information on research and development spending, government contract revenue and risk factors. Current reports on Form 8‑K highlight specific events, such as the exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart’s oral COVID-19 vaccine candidate, updates on the BARDA-funded Project NextGen Phase 2b trial, lease terminations related to cost reduction efforts, and governance and listing developments.
For trading status, Vaxart’s 8‑K filings and the Form 25 filed by Nasdaq Stock Market LLC document the suspension and removal of the company’s common stock from Nasdaq and its quotation on the OTCQX Best Market under the symbol VXRT. These filings provide the official record of Vaxart’s transition from a national exchange to OTCQX and the conditions that led to delisting.
On this page, users can also monitor any registration statements, prospectus supplements and other capital markets filings that Vaxart uses to raise funds or register securities, as well as any future proxy materials related to corporate actions. Stock Titan’s AI tools summarize long forms such as 10‑K and 10‑Q, highlight key sections on clinical programs, government contracts and collaboration terms, and surface important items from 8‑Ks so that readers can quickly understand how each filing may relate to Vaxart’s oral vaccine development and trading status.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported a routine tax-related share disposition tied to vested RSUs. On March 28, 2026, 3,924 shares of common stock were withheld by the company at $0.65 per share to cover income tax obligations. After this, Tucker held 882,811 common shares directly, plus 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse, both reported as indirect ownership.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported a routine tax-withholding transaction involving company stock. On March 28, 2026, 3,292 shares of Common Stock were withheld by Vaxart at $0.65 per share to cover income tax obligations from vested RSUs.
After this withholding, Cummings directly holds 924,177 shares of Vaxart common stock, including 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. This event reflects tax settlement on equity compensation rather than an open-market sale.
Vaxart, Inc. executive Edward B. Berg, SVP and General Counsel, reported a tax-related share disposition tied to restricted stock units. On the RSU vesting date, 36,418 shares of common stock at $0.694 per share were withheld by the company to satisfy income tax obligations, rather than sold in the open market. After this withholding, Berg directly holds 755,368 common shares, including 70,781 shares previously acquired under Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc.’s Chief Medical Officer, James F. Cummings, reported a routine tax-related share disposition. On March 24, 2026, 30,551 shares of common stock were withheld by the company at $0.694 per share to cover income tax obligations from vested RSUs. After this withholding, he directly holds 927,469 common shares, which includes 75,618 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan. This event reflects compensation-related tax settlement rather than an open-market sale.
Vaxart, Inc. President and CEO Steven Lo reported a tax-related share disposition tied to restricted stock units (RSUs). On March 24, 2026, 126,028 shares of common stock were withheld by the company to satisfy income tax withholding and remittance obligations upon RSU vesting, rather than sold in the open market.
Following this withholding, Lo directly holds 2,485,606 shares of Vaxart common stock and indirectly holds 100,000 shares through the Lo Family Trust. The filing reflects routine equity compensation and associated tax treatment rather than a discretionary buy or sell decision.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported a tax-withholding share disposition related to vested RSUs. On March 24, 2026, 36,418 shares of common stock were withheld by the company at $0.694 per share to cover income tax obligations on RSUs that vested that day.
After this non-market, tax-related disposition, Tucker directly holds 886,735 shares. He also has indirect holdings of 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse, as reflected in the filing’s ownership entries.
Vaxart, Inc. reported an insider equity transaction by SVP and General Counsel Edward B. Berg related to tax withholding on vested stock awards. On March 18, 2026, 8,072 shares of common stock were disposed of at $0.6346 per share to satisfy income tax withholding obligations in connection with the net settlement of RSUs that vested on that date. This was not an open-market sale but a routine, issuer-withheld share disposition for taxes. Following the transaction, Berg directly held 791,786 common shares, which includes 70,781 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported a routine share withholding tied to restricted stock units. On March 18, 2026, 6,772 shares of common stock were withheld at $0.6346 per share to cover income tax obligations for vested RSUs. After this tax-withholding disposition, he directly holds 958,020 shares of Vaxart common stock, which includes 75,618 shares acquired under the 2022 Employee Stock Purchase Plan.
Vaxart, Inc. President and CEO Steven Lo reported a tax-related share disposition tied to RSU vesting. On March 18, 2026, 22,425 shares of common stock were withheld by the company at $0.6346 per share to cover income tax obligations on vested RSUs, a non-market transaction coded as "F." After this withholding, Lo directly owned 2,611,634 common shares and indirectly held 100,000 additional shares through the Lo Family Trust, indicating that his overall equity stake remains substantial despite the routine tax withholding.
Vaxart, Inc. senior executive Sean Tucker reported a routine tax-related share disposition tied to restricted stock unit vesting. On March 18, 2026, 8,072 shares of common stock were withheld by the company to cover income tax obligations from RSUs that vested on that date, a non-market transaction rather than an open-market sale. After this withholding, Tucker directly holds 923,153 common shares and has additional indirect holdings of 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse.